Conditions: 0.25 mg · twelve weeks · nausea.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
What is the causal chain, and where does it stop being established?
twelve weeks at 0.25 mg is 84 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 0.25 mg back by 84 days. Whether that reduces nausea depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 0.25 mg is 0.25 mg on day 1 and on day 84. A symptom driven by the rate of change has 84 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot nausea against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Concretely, the published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Nothing here is medical advice, and research-use compounds are not approved for human use.
The top of the schedule is not the target. The working dose is.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemMechanically, this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Four half-lives between steps, minimum. Work it out for your agent.
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
It helps to be literal here: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Hold rather than escalate while symptoms are active. Always.
edited 1 Sept 2025 by esther_vandeVelde — added the citation requested in comments
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Stepping back is a normal adjustment, not a failure.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.